BR0110419A - Esteróides de 3-nitrogênio-6,7-dioxigênio e usos relacionados aos mesmos - Google Patents

Esteróides de 3-nitrogênio-6,7-dioxigênio e usos relacionados aos mesmos

Info

Publication number
BR0110419A
BR0110419A BR0110419-5A BR0110419A BR0110419A BR 0110419 A BR0110419 A BR 0110419A BR 0110419 A BR0110419 A BR 0110419A BR 0110419 A BR0110419 A BR 0110419A
Authority
BR
Brazil
Prior art keywords
nitrogen
oxygen
carbons
silicon
hydrogen
Prior art date
Application number
BR0110419-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Jeffery R Raymond
Claudia E Kasserra
Yaping Shen
Original Assignee
Inflazyme Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflazyme Pharm Ltd filed Critical Inflazyme Pharm Ltd
Publication of BR0110419A publication Critical patent/BR0110419A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0011—Unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0042—Nitrogen only
    • C07J71/0047—Nitrogen only at position 2(3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0057—Nitrogen and oxygen
    • C07J71/0063—Nitrogen and oxygen at position 2(3)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0110419-5A 2000-04-28 2001-04-30 Esteróides de 3-nitrogênio-6,7-dioxigênio e usos relacionados aos mesmos BR0110419A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20061700P 2000-04-28 2000-04-28
PCT/CA2001/000581 WO2001083512A1 (en) 2000-04-28 2001-04-30 3-nitrogen-6,7-dioxygen steroids and uses related thereto

Publications (1)

Publication Number Publication Date
BR0110419A true BR0110419A (pt) 2004-02-25

Family

ID=22742458

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110419-5A BR0110419A (pt) 2000-04-28 2001-04-30 Esteróides de 3-nitrogênio-6,7-dioxigênio e usos relacionados aos mesmos

Country Status (33)

Country Link
US (4) US20040034216A1 (cg-RX-API-DMAC10.html)
EP (1) EP1278763B1 (cg-RX-API-DMAC10.html)
JP (1) JP2003531916A (cg-RX-API-DMAC10.html)
KR (1) KR20030045671A (cg-RX-API-DMAC10.html)
CN (1) CN1214039C (cg-RX-API-DMAC10.html)
AP (1) AP1825A (cg-RX-API-DMAC10.html)
AT (1) ATE353909T1 (cg-RX-API-DMAC10.html)
AU (2) AU2001252084B2 (cg-RX-API-DMAC10.html)
BG (1) BG107289A (cg-RX-API-DMAC10.html)
BR (1) BR0110419A (cg-RX-API-DMAC10.html)
CA (1) CA2418748A1 (cg-RX-API-DMAC10.html)
CO (1) CO5590904A2 (cg-RX-API-DMAC10.html)
DE (1) DE60126597T2 (cg-RX-API-DMAC10.html)
DK (1) DK1278763T3 (cg-RX-API-DMAC10.html)
DZ (1) DZ3355A1 (cg-RX-API-DMAC10.html)
EE (1) EE200200613A (cg-RX-API-DMAC10.html)
ES (1) ES2282247T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20020944A2 (cg-RX-API-DMAC10.html)
HU (1) HUP0300908A2 (cg-RX-API-DMAC10.html)
IL (2) IL152448A0 (cg-RX-API-DMAC10.html)
MA (1) MA25808A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA02010645A (cg-RX-API-DMAC10.html)
NO (1) NO324873B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ522181A (cg-RX-API-DMAC10.html)
OA (1) OA12255A (cg-RX-API-DMAC10.html)
PL (1) PL365798A1 (cg-RX-API-DMAC10.html)
PT (1) PT1278763E (cg-RX-API-DMAC10.html)
RU (1) RU2291873C2 (cg-RX-API-DMAC10.html)
SK (1) SK15692002A3 (cg-RX-API-DMAC10.html)
UA (1) UA79229C2 (cg-RX-API-DMAC10.html)
WO (1) WO2001083512A1 (cg-RX-API-DMAC10.html)
YU (1) YU88102A (cg-RX-API-DMAC10.html)
ZA (1) ZA200208631B (cg-RX-API-DMAC10.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
SK15692002A3 (sk) * 2000-04-28 2003-11-04 Inflazyme Pharmaceuticals Limited 3-Amino-6,7-dioxygénované steroidy a s nimi súvisiace použitie
AU2002303425A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
US6696580B2 (en) 2001-05-22 2004-02-24 Inflazyme Pharmaceuticals Ltd. Process for the production of 6,7-diols of steroidal compounds
EP1526140B1 (en) * 2002-08-01 2008-11-05 Astellas Pharma Inc. Potassium-dependent sodium-calcium exchanger
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20110209699A1 (en) * 2003-07-31 2011-09-01 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20080051382A1 (en) * 2003-10-20 2008-02-28 Inflazyme Pharmaceuticals Ltd. Crystalline Forms of 3-Beta-Amino 17-Methylene Androstane-6-Alpha 7-Beta-Diol Hydrochloride
EP1680441A1 (fr) * 2003-10-20 2006-07-19 Inflazyme Pharmaceuticals, Ltd. Formes cristallines du chlorhydrate de 3-beta-amino, 17-methylene, androstane-6-alpha, 7-beta-diol
FR2861077B1 (fr) * 2003-10-20 2006-03-03 Aventis Pharma Sa Formes cristallines du chlorydrate de 3-beta-amino, 17-methylene, androstane-6-alpha, 7-beta-diol
US20050222049A1 (en) * 2004-03-31 2005-10-06 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20050227927A1 (en) * 2004-03-31 2005-10-13 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20090317477A1 (en) * 2004-03-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
AU2008326386B2 (en) * 2007-11-21 2014-07-31 The Procter & Gamble Company Preparations, methods and kits useful for treatment of cough
JP5655243B2 (ja) * 2009-10-19 2015-01-21 国立大学法人 熊本大学 インドキシル硫酸の産生の阻害剤のスクリーニング方法、インドキシル硫酸代謝産生阻害剤、及び腎障害軽減剤
ES2654584T3 (es) 2010-01-15 2018-02-14 Suzhou Neupharma Co., Ltd Ciertas entidades químicas, composiciones y métodos
MX375112B (es) 2010-07-09 2025-03-06 Biogen Hemophilia Inc Polipéptidos de factor ix y métodos para usarlos.
EP3453714B1 (en) 2011-02-02 2020-11-04 Suzhou Neupharma Co., Ltd Cardenolide and bufadienolide 3-carbonate and 3-carbamate derivatives for the treatment of cancer and compositions thereof
EP3453713B1 (en) * 2012-04-29 2021-09-08 Neupharma, Inc. Bufadienolide compounds substituted in position 3 by an amine group for use in the treatment of cancer
WO2014052490A1 (en) 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
EP2970122B1 (en) 2013-03-14 2019-05-08 Aquinox Pharmaceuticals (Canada) Inc. Ship1 modulators
US10100056B2 (en) 2013-03-14 2018-10-16 Aquinox Pharmaceuticals (Canada) Inc. SHIP1 modulators and methods related thereto
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
CN104744547B (zh) * 2013-12-27 2017-02-15 天津医科大学 一种抗乳腺癌转移作用的孕甾烷生物碱衍生物及医药用途
EP3313811A1 (en) 2015-06-26 2018-05-02 Aquinox Pharmaceuticals (Canada) Inc. Crystalline solid forms of the acetate salt of (1s,3s,4r)-4-((3as,4r,5s,7as)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1h-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol
WO2017127753A1 (en) 2016-01-20 2017-07-27 Aquinox Pharmaceuticals (Canada) Inc. Synthesis of a substituted indene derivative
WO2019195692A1 (en) * 2018-04-06 2019-10-10 Aquinox Pharmaceuticals (Canada) Inc. Hexadecahydro-1h-cyclopenta[a]phenanthrene derivatives useful in treating pain and inflammation
JP2021526546A (ja) 2018-04-06 2021-10-07 アキノックス ファーマシューティカルス(カナダ)インク. 疼痛及び炎症を治療するのに有用なインデン誘導体
JP2021526545A (ja) 2018-04-06 2021-10-07 アキノックス ファーマシューティカルス(カナダ)インク. 疼痛及び炎症を治療するのに有用なインデン誘導体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3682983A (en) * 1969-11-12 1972-08-08 Klaus Prezewowsky Preparation of {66 {11 {11 -17 ethinyl steroids
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
ATE188036T1 (de) 1990-01-18 2000-01-15 Cura Nominees Pty Ltd Glykoalkaloide
US5877185A (en) 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
CA2086221C (en) * 1992-12-23 2003-07-15 Raymond J. Andersen Contignasterol, and related 3-alpha hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroids useful as anti-inflammatory and anti-thrombosis agent
CA2157594A1 (en) * 1993-03-10 1994-09-15 Leah L. Frye Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
US5817632A (en) * 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
WO1996036230A1 (en) 1995-05-16 1996-11-21 The Salk Institute For Biological Studies Modulators for new members of the steroid/thyroid superfamily of receptors
US5874597A (en) 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
US6060465A (en) 1997-02-06 2000-05-09 Miljkovic; Dusan Bile acids and their derivatives as glycoregulatory agents
ATE269086T1 (de) 1998-03-06 2004-07-15 Univ Brigham Young Antibiotische steroidderivate
SK15692002A3 (sk) * 2000-04-28 2003-11-04 Inflazyme Pharmaceuticals Limited 3-Amino-6,7-dioxygénované steroidy a s nimi súvisiace použitie

Also Published As

Publication number Publication date
CN1430625A (zh) 2003-07-16
NO20025106L (no) 2002-12-18
PL365798A1 (en) 2005-01-10
US20040138186A1 (en) 2004-07-15
WO2001083512A1 (en) 2001-11-08
DE60126597D1 (de) 2007-03-29
US6635629B2 (en) 2003-10-21
MA25808A1 (fr) 2003-07-01
NO20025106D0 (no) 2002-10-24
AU2001252084B2 (en) 2006-07-06
ATE353909T1 (de) 2007-03-15
DK1278763T3 (da) 2007-06-11
IL152448A (en) 2006-12-31
MXPA02010645A (es) 2004-04-20
CA2418748A1 (en) 2001-11-08
AU5208401A (en) 2001-11-12
IL152448A0 (en) 2003-05-29
US7112580B2 (en) 2006-09-26
HK1050694A1 (en) 2003-07-04
CN1214039C (zh) 2005-08-10
SK15692002A3 (sk) 2003-11-04
EP1278763A1 (en) 2003-01-29
YU88102A (sh) 2006-01-16
JP2003531916A (ja) 2003-10-28
EP1278763B1 (en) 2007-02-14
HUP0300908A2 (hu) 2003-07-28
US20040034216A1 (en) 2004-02-19
NO324873B1 (no) 2007-12-17
HRP20020944A2 (en) 2004-02-29
NZ522181A (en) 2005-04-29
US20020072510A1 (en) 2002-06-13
BG107289A (bg) 2003-07-31
US20050215534A9 (en) 2005-09-29
PT1278763E (pt) 2007-05-31
ZA200208631B (en) 2004-02-23
DZ3355A1 (fr) 2001-11-08
EE200200613A (et) 2004-04-15
US20070060553A1 (en) 2007-03-15
CO5590904A2 (es) 2005-12-30
AP1825A (en) 2008-02-03
AP2002002659A0 (en) 2002-12-31
OA12255A (en) 2006-05-11
DE60126597T2 (de) 2007-10-31
ES2282247T3 (es) 2007-10-16
UA79229C2 (en) 2007-06-11
KR20030045671A (ko) 2003-06-11
RU2291873C2 (ru) 2007-01-20

Similar Documents

Publication Publication Date Title
AP1825A (en) 3-Nitrogen-6, 7-dioxygen steroids and uses related thereto.
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
PE20040937A1 (es) Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4)
HUP0203122A2 (hu) Fab I inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BR9813835A (pt) Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica
CA2333703A1 (en) Isothiazole derivatives useful as anticancer agents
BRPI0714761B8 (pt) formulações compreendendo compostos cíclicos
CA2119572A1 (en) Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
HUP0100950A2 (hu) Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények
TNSN03110A1 (en) Azaindoles.
ID27178A (id) Senyawa aminosikloheksil eter dan penggunaannya
BR0109467A (pt) Composto derivados de (beta)-aminoácidos cìclicos, composição farmacêutica, método de tratamento de condições ou doenças mediadas por mps, tnf, aggrecanase ou uma combinação destes em mamìferos e uso de composto
FI73678B (fi) Foerfarande foer framstaellning av farmaceutiskt anvaendbara azabicyklo-oktankarboxylsyror.
MXPA05007496A (es) Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes.
SE9701304D0 (sv) Compounds
BR0310032A (pt) Derivados de benzoxazina como moduladores de 5-ht6 e usos dos mesmos
BRPI0408248A (pt) derivados azabicìclicos de piridiloximetila e de benzisoxazol
BR0308133A (pt) Forma polimórfica cristalina de cloridrato de irinotecan
BRPI0315958B8 (pt) composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
EP1277744A4 (en) OXADIAZONE DERIVATIVES WITH ANTIBODY EFFECT
BR9910628A (pt) Uso de um composto da série da benzofuroxana, composição farmacêutica, e, processos para a preparação de uma formulação parenteral e para o tratamento de um mamìfero, incluindo um ser humano, de doenças cardìacas da coronária
BRPI0517204A (pt) sulfato de levosalbutamol cristalino (forma i), sulfato de levosalbutamol cristalino (forma ii), sulfato de levosalbutamol cristalino (forma iii), processo para preparar a forma i do sulfato de levosalbutamol cristalino, processo para preparar a forma ii do sulfato de levosalbutamol cristalino, processo para preparar a forma iii do sulfato de levosalbutamol, composição farmacêutica, composto, combinação, pó seco para inalador, processo para preparar um pó seco para inalador, processo para preparar uma composição famacêutica, processo para fabricação de uma composição farmacêutica, método para tratamento de um mamìfero, e uso de uma combinação de salbutamol
BR9809496A (pt) Composto, processo para produzi-lo, uso do mesmo, preparação farmacêutica, e, processo para tratar pacientes necessitados de tratamento.
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
BR0200843A (pt) Compostos farmaceuticamente ativos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.